Search results for "Dose–response relationship"

showing 10 items of 82 documents

Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease

2014

ABSTRACT This was a phase 1B, dose-ranging, multicenter, pharmacokinetics, and safety study of cyclodextrin-based posaconazole intravenous (i.v.) solution administered through a central line to subjects at high risk for invasive fungal disease (part 1 of a 2-part study [phase 1B/3]). Initially, the safety and tolerability of single-dose posaconazole i.v. 200 mg ( n = 10) were compared with those of a placebo ( n = 11). Subsequently, 2 doses were evaluated, posaconazole i.v. 200 mg once daily (q.d.) ( n = 21) and 300 mg q.d. ( n = 24). The subjects received twice-daily (b.i.d.) posaconazole i.v. on day 1, followed by 13 days of posaconazole i.v. q.d., then 14 days of posaconazole oral suspen…

AdultMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsPhases of clinical researchPharmacologyPlaceboGastroenterologyCohort StudiesPharmacokineticsInternal medicinemedicineHumansPharmacology (medical)DosingAgedPharmacologyDose-Response Relationship Drugbusiness.industryMiddle AgedTriazolesPharmaceutical SolutionsDose–response relationshipInfectious DiseasesMycosesTolerabilityInjections IntravenousCohortFemalebusinessmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Nonlinear pharmacokinetics of fluvoxamine and gender differences.

1998

This prospective study assessed fluvoxamine serum concentrations under two different fixed doses. The study included 15 male and female patients who met the DSM-III-R criteria for major depression. They were prescribed 50 mg fluvoxamine twice a day for 2 weeks and 100 mg twice a day thereafter. Drug monitoring was carried out on days 14 and 28. Fluvoxamine serum concentrations were highly variable between patients. After the dose was doubled, the serum concentrations of fluvoxamine increased disproportionately (mean, 3.4-fold), and there was a significantly (p < 0.05) more pronounced increase in men (4.6-fold) than in women (2.4-fold). These results provide evidence of nonlinear, sex-depend…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentFluvoxamineGastroenterologySex FactorsPharmacokineticsOral administrationInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyAgedPharmacologyAged 80 and overChemotherapyDepressive DisorderDose-Response Relationship Drugbusiness.industryNonlinear pharmacokineticsMiddle AgedDose–response relationshipFluvoxamineAnesthesiaAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugTherapeutic drug monitoring
researchProduct

Pulsatile versus continuous oxytocin infusion for the oxytocin challenge test.

1994

In a prospective study, 140 patients had an oxytocin challenge test with either a continuous or a pulsed infusion (one minute of infusion in every five minutes). Both infusion regimens had similar success rates in terms of uterine contractions (97.1 vs 98.6%). The potency ratio (pulsed versus continuous infusion) was significant at 2.7 (1.27 to 5.2), which means that more uterine activity was induced with each mU of oxytocin with pulsatile than with continuous administration. The total amount of oxytocin required to obtain three good contractions in 10 minutes was about 40% less with pulsed administration than with continuous infusion, but the test took 40 minutes longer with the pulsed tha…

AdultOxytocin challenge testContinuous infusionPulsatile flowOxytocinDrug Administration ScheduleUterine contractionUterine ContractionPregnancyMedicineHumansInfusions IntravenousInfusion PumpsUterine activityDose-Response Relationship Drugbusiness.industryPotency ratioInfant NewbornObstetrics and GynecologyGeneral MedicineDose–response relationshipOxytocinAnesthesiaPulsatile FlowFemalemedicine.symptombusinessmedicine.drugArchives of gynecology and obstetrics
researchProduct

Beta-adrenergic blocking activity and haemodynamic effects in man of K� 1313, a new beta-adrenergic antagonist

1971

The beta-adrenergic blocking activity and haemodynamic effects of o-[2-hydroxy-3-(isopropylamino)-propoxy]-benzonitril (Ko 1313) have been studied in 22 patients. Antagonism of isoproterenol-induced tachycardia was used as a measure of the beta-adrenergic blocking activity. Ko 1313 1.0 mg had its maximum beta-adrenoceptor blocking effect 5–30 min after intravenous injection. Ko 1313 10.0 mg produced maximum betablockade 1–4 h after oral administration. 1.0 mg Ko 1313 injected intravenously had approximately the same beta-adrenergic blocking effect as 1.0 mg propranolol also given intravenously. After intravenous administration Ko 1313 was 3–4 times as potent as the same dose given orally. A…

AdultTachycardiamedicine.medical_specialtyCardiac outputAdolescentAdrenergic receptorCardiac VolumeAdrenergic beta-AntagonistsAdministration OralBlood Pressure1-PropanolPropranololPharmacologyElectrocardiographyHeart RateOral administrationInternal medicineNitrilesHeart ratemedicineHumansPharmacology (medical)Cardiac OutputPharmacologyBeta-adrenergic blocking agentPropylaminesbusiness.industryHemodynamicsIsoproterenolGeneral MedicineMiddle AgedAmino AlcoholsPropranololDose–response relationshipEndocrinologyInjections IntravenousSympatholyticsVascular Resistancemedicine.symptombusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist.

2011

High daily doses of gonadotrophin-releasing hormone (GnRH) antagonists during the follicular phase of ovarian stimulation were associated with low implantation rates. To test if this occurred because of profound pituitary suppression, the pituitary response was suppressed with a high-dose GnRH antagonist and recombinant LH (rLH) was added back to correct the implantation rate. An open-label, randomized, controlled, prospective clinical study in 60 patients undergoing IVF was performed. GnRH antagonist was initiated on day 6 of stimulation (2 mg/day) together with 375 IU rLH, and maintained until the day of HCG administration. Controls received 0.25 mg/day GnRH antagonist. Fluctuating LH con…

Adultendocrine systemmedicine.medical_specialtymedicine.medical_treatmentStimulationlaw.inventionGonadotropin-Releasing HormoneOvulation InductionlawInternal medicineFollicular phaseMedicineHumansProspective StudiesAdverse effectProspective cohort studyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyLuteinizing HormoneRecombinant ProteinsDose–response relationshipEndocrinologyReproductive MedicineRecombinant DNAOvulation inductionFemalebusinesshormones hormone substitutes and hormone antagonistsDevelopmental BiologyHormoneReproductive biomedicine online
researchProduct

Developmental Changes and Daily Rhythm in Melatonin-Induced Inhibition of 3′,5′-Cyclic AMP Accumulation in the Rat Pituitary

1990

Melatonin's transduction mechanisms were investigated using in vitro cultured anterior hemipituitaries. Melatonin inhibited cAMP and 3',5'-cyclic GMP accumulation in neonatal rat anterior pituitary stimulated with LHRH. Maximal inhibitory effect was reached within 25 min and persisted for at least 20 min. Inhibition of cAMP accumulation is specific for melatonin because its analogs N-acetylserotonin and 5-methoxytryptamine are 1000 times less potent. Melatonin effect is age- and time-dependent. Marked inhibition was observed in 5-, 10-, and 14-day-old rats but not in 29-day-old ones. Melatonin was significantly more potent when applied at the end of the light period as compared with the fir…

Agingendocrine systemmedicine.medical_specialtyPituitary glandTime FactorsGonadotropin-releasing hormoneIn Vitro TechniquesBiologyGonadotropin-Releasing HormoneMelatoninEndocrinologyAnterior pituitaryInternal medicineCyclic AMPmedicineAnimalsCircadian rhythmCyclic GMPMelatoninDose-Response Relationship DrugRats Inbred StrainsCircadian RhythmRatsDose–response relationshipEndocrinologymedicine.anatomical_structurePituitary GlandSecond messenger systemhormones hormone substitutes and hormone antagonistsEndocrine glandmedicine.drugEndocrinology
researchProduct

Anti-arthritic activity of a lipophilic woad (Isatis tinctoria) extract

2006

A dichloromethane extract of Isatis tinctoria was tested in the adjuvant-induced arthritis model in rats. The extract (150 mg/kg p. o.) leads to a significant reduction of paw oedema. Radiographic, histological and clinical assessment confirmed reduced damage of cartilage and signs of inflammatory response in comparison to untreated control. No significant differences were observed in the tissular levels of cyclooxygenases 1 and -2, and of inducible nitric oxide synthase in Isatis treated and untreated animals. High dose treatment with Isatis extract for two weeks did not result in macroscopic lesions of the gastric mucosa.

Anti-Inflammatory AgentsAdministration OralPharmaceutical ScienceArthritisPharmacognosyAnalytical Chemistrylaw.inventionArthritis RheumatoidMicelawDrug DiscoveryGastric mucosamedicineAnimalsEdemaIsatisPharmacologyDose-Response Relationship DrugbiologyTraditional medicinePlant Extractsbusiness.industryMacrophagesOrganic ChemistryIsatisbiology.organism_classificationmedicine.diseaseRatsIsatis tinctoriaRadiographyNitric oxide synthaseDose–response relationshipmedicine.anatomical_structureComplementary and alternative medicineRats Inbred Lewbiology.proteinMolecular MedicineFemalePhytotherapybusinessPhytotherapyPlanta Medica
researchProduct

ANALYSIS OF THE DOSE-RESPONSE CURVE TO SODIUM NITRITE IN ISOLATED RAT AORTA

1978

Aortachemistry.chemical_compoundDose–response relationshipChromatographychemistrymedicine.arterymedicineSodium nitrite
researchProduct

Mildronate treatment improves functional recovery following middle cerebral artery occlusion in rats

2011

Mildronate (3-(2,2,2-trimethylhydrazinium) propionate) is an inhibitor of l-carnitine biosynthesis and an anti-ischemic drug. In the present study, we investigated the effects of mildronate in rats following focal cerebral ischemia. Male Wistar rats were subjected to transient occlusion of the middle cerebral artery (MCAO) for 90min, followed by the intraperitoneal administration of mildronate at doses of 100 and 200mg/kg 2h after reperfusion and then daily for an additional 14days. The beam-walking, rota-rod and cylinder tests were used to assess sensorimotor function, and vibrissae-evoked forelimb-placing and limb-placing tests examined responses to tactile and proprioceptive stimulation.…

Brain InfarctionMaleIschemiaStimulationPharmacologyRotarod performance testBrain ischemiaBehavioral NeuroscienceAdjuvants ImmunologicTandem Mass SpectrometryCarnitinemedicine.arterymedicineAnimalsRats WistarStrokeChromatography High Pressure LiquidAnalysis of VarianceDose-Response Relationship Drugbusiness.industryExtremitiesInfarction Middle Cerebral ArteryRecovery of Functionmedicine.diseaseRatsBetaineDose–response relationshipRotarod Performance TestVibrissaeMiddle cerebral arterySystemic administrationbusinessNeuroscienceLocomotionPsychomotor PerformanceMethylhydrazinesBehavioural Brain Research
researchProduct

The extracorporeal perfusion of the female pig detrusor as an experimental model for the study of bladder contractility.

2007

Aims The objective of the study was to establish an experimental model for the extracorporeal perfusion of the pig detrusor. In order to validate this model we examined some biochemical parameters and determined the effect of carbachol on the contractility of perfused female pig bladders. Methods Twenty-six pig bladders were perfused with Krebs–Ringer bicarbonate-glucose buffer for a period up to 5 hr with the aim to preserve a viable organ, which would be responsive to contraction-inducing agents. The intravesical pressure of the bladder as well as the intraarterial pressure of the vesical arteries were recorded before and after administration of carbachol. Results The perfusate pH, lactat…

CarbacholUrologySus scrofaUrinary BladderPig bladderBlood PressureCholinergic AgonistsContractilitymedicineAnimalsDose-Response Relationship Drugbusiness.industryExperimental modelMuscle SmoothExtracorporeal perfusionDose–response relationshipmedicine.anatomical_structureAnesthesiaModels AnimalCarbacholFemaleNeurology (clinical)Vesical arteriesbusinessPerfusionmedicine.drugMuscle ContractionNeurourology and urodynamics
researchProduct